Mary-Lynn Cesar, Kapitall: Approval of Congress is at an all-time low, but a bill in the Senate could help pharmaceutical stocks reach highs.
Congressional approval fell to its lowest level in almost 40 years due to lingering bad feelings from last month’s government shutdown.
Read more from Kapitall: Value Investing: John Thompson Says to Ditch Tech, Buy Big Banks
According to a Gallup poll released on Tuesday, the approval rating currently sits at 9%, bringing the year-to-date approval rating to 14%, and increasing the likelihood that 2013 will result in the lowest yearly average Congressional approval rating in Gallup history.
Business as usual
The Gallup poll found that 59% of survey participants cited inaction and partisan gridlock as the leading reason behind their disapproval of Congress. And in the four weeks since Congress returned to work, the discord has reappeared: GOP senators blocked two judicial nominees, and House Speaker John Boehner stated his refusal to conference over the Senate’s immigration bill.
H.R. 3204: Drug Quality and Security Act
But Congress has made slight headway in some regards: the Senate voted 97-1 on Tuesday to advance the Drug Quality and Security Act, a bill that will place compounding pharmacies under more Food and Drug Administration (FDA) oversight. The bill, which has overwhelming bipartisan support, was passed by the House in September and requires Senate approval before President Obama can sign it into law.
Compounding pharmacies mix or change ingredients to create tailored medications for the needs of specific patients. Under the proposed legislation, these pharmacies would be prohibited from copying widely available, FDA-approved drugs in their compounded medications.
If Congress passes the Drug Quality and Security Act, pharmaceutical companies may see increased sales due to this restriction, which would bar compounding pharmacies from copying their drugs. This inspired us to look for investment opportunities among pharmaceutical stocks for our following screen.
To begin, we constructed a universe of stocks belonging to biotechnology and drug manufacturing industries. We then screened that group for stocks with rising gross profit margins year-over-year for the last three years.
Gross margin is the percentage of profit a company makes for each dollar it generates in sales, after deducting production expenses. Examples of these expenses include operating costs, payroll, and taxes.
Gross Margin = Gross Profit / Revenue
The higher the percentage, the greater the gross profits a company takes from its revenue. When a company has rising gross margins, it indicates that the firm is in control of its costs.We then narrowed down that list to companies with FDA-approved drugs on the market. This left us with three pharmaceutical stocks on our list.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV